Literature DB >> 19857379

Update on invasive opportunistic mycoses: clinical trials review, 2008-2009.

Andreas H Groll1.   

Abstract

Invasive fungal infections remain major causes for morbidity and mortality in severely ill or immunocompromised patients. The past decade saw major expansion in the antifungal armamentarium, and the precise role of newer antifungal agents continues to be defined through clinical trials. This article summarizes five of the most relevant clinical trials related to prevention and treatment of opportunistic fungal infections in adult patients published between 2008 and 2009.

Entities:  

Year:  2009        PMID： 19857379     DOI： 10.1007/s11908-009-0060-0

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN： 1523-3847            Impact factor:   3.725


  9 in total

1.  Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.

Authors:  Johan Maertens; Issam Raad; George Petrikkos; Marc Boogaerts; Dominik Selleslag; Finn B Petersen; Carole A Sable; Nicholas A Kartsonis; Angela Ngai; Arlene Taylor; Thomas F Patterson; David W Denning; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2004-11-09       Impact factor: 9.079

2.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.

Authors:  Oliver A Cornely; Johan Maertens; Drew J Winston; John Perfect; Andrew J Ullmann; Thomas J Walsh; David Helfgott; Jerzy Holowiecki; Dick Stockelberg; Yeow-Tee Goh; Mario Petrini; Cathy Hardalo; Ramachandran Suresh; David Angulo-Gonzalez
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

3.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.

Authors:  Andrew J Ullmann; Jeffrey H Lipton; David H Vesole; Pranatharthi Chandrasekar; Amelia Langston; Stefano R Tarantolo; Hildegard Greinix; Wellington Morais de Azevedo; Vijay Reddy; Navdeep Boparai; Lisa Pedicone; Hernando Patino; Simon Durrant
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

4.  Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling.

Authors:  A H Groll; D Mickiene; R Petraitiene; V Petraitis; C A Lyman; J S Bacher; S C Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

5.  Treatment-related risk factors for hospital mortality in Candida bloodstream infections.

Authors:  Andrew J Labelle; Scott T Micek; Nareg Roubinian; Marin H Kollef
Journal:  Crit Care Med       Date:  2008-11       Impact factor: 7.598

6.  Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial.

Authors:  Mindy G Schuster; John E Edwards; Jack D Sobel; Rabih O Darouiche; Adolf W Karchmer; Susan Hadley; Gus Slotman; Helene Panzer; Pinaki Biswas; John H Rex
Journal:  Ann Intern Med       Date:  2008-07-15       Impact factor: 25.391

7.  Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.

Authors:  Andres Pascual; Thierry Calandra; Saskia Bolay; Thierry Buclin; Jacques Bille; Oscar Marchetti
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

8.  Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial.

Authors:  Bart J Rijnders; Jan J Cornelissen; Lennert Slobbe; Martin J Becker; Jeanette K Doorduijn; Wim C J Hop; Elisabeth J Ruijgrok; Bob Löwenberg; Arnold Vulto; Pieternella J Lugtenburg; Siem de Marie
Journal:  Clin Infect Dis       Date:  2008-05-01       Impact factor: 9.079

9.  A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis.

Authors:  Robert F Betts; Marcio Nucci; Deepak Talwar; Marcelo Gareca; Flavio Queiroz-Telles; Roger J Bedimo; Raoul Herbrecht; Guillermo Ruiz-Palacios; Jo-Anne H Young; John W Baddley; Kim M Strohmaier; Kimberly A Tucker; Arlene F Taylor; Nicholas A Kartsonis
Journal:  Clin Infect Dis       Date:  2009-06-15       Impact factor: 9.079
  9 in total
  1 in total

1.  Usefulness of molecular biology performed with formaldehyde-fixed paraffin embedded tissue for the diagnosis of combined pulmonary invasive mucormycosis and aspergillosis in an immunocompromised patient.

Authors:  Véronique Hofman; Abdelmajid Dhouibi; Catherine Butori; Bernard Padovani; Martine Gari-Toussaint; Dea Garcia-Hermoso; Michèle Baumann; Nicolas Vénissac; Gieri Cathomas; Paul Hofman
Journal:  Diagn Pathol       Date:  2010-01-08       Impact factor: 2.644
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.